Effect of cytochrome P450 2C19 gene polymorphism on clopidogrel antiplatelet therapy
10.13699/j.cnki.1001-6821.2017.19.017
- VernacularTitle:细胞色素P450 2C19基因多态性对氯吡格雷抗血小板作用的影响
- Author:
Hui MA
1
;
Hui-Yi L(U)
;
Xiao-Jie YU
;
Zeng-Chun HU
;
Li-Jing SUN
;
Li-Chun CHENG
;
Ce ZHANG
Author Information
1. 大连医科大学附属第二医院药学部
- Keywords:
gene polymorphism;
clopidogrel;
percutaneous coronary intervention;
soluble P-selectin;
platelet glycoprotein GPⅡb/Ⅲa fibrinogen receptor
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(19):1909-1911
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of cytochrome P450 2C19 (CYP2C19) gene polymorphism on the antiplatelet therapy of clopidogrel in patients who underwent percutaneous coronary intervention (PCI).Methods Fifty-five patients who underwent PCI,as well as twenty-three healthy subjects,were enrolled in this study.The genotypes of the samples were identified by gene chips hybridization.The contents of soluble P-selectin (CD62p) and platelet glycoprotein GP Ⅱ b/Ⅲ a fibrinogen receptor(PAC-1) in patients who underwent PCI were detected by flow cytometry (FCM).The expressions of platelet activation markers were calculated according to interquartile range method.Results Seven patients with CYP2C19 * 2/* 2 genotypes were poor metabolizers,while twenty-eight patients with CYP2C19 * 1/* 2,CYP2C19 * 1/ * 3 were intermediate metabolizers,twenty patients with CYP2C19 * 1/ * 1 were extensive metabolizers.In intermediate metabolism (* 1/* 2),intermediate metabolism (* 1/* 3) and poor metabolism group,the CD62p expressions were (6.73 ± 5.69) ％,(10.94 ± 9.80) ％,(14.35 ± 6.24) ％,(16.80 ± 13.65) ％,respectively,statistically significant differences were found when compared with the control group;The PAC-1 expressions were (1.06 ± 0.69) ％,(2.10 ± 4.09) ％,(2.37 ± 3.15) ％,(2.89 ± 2.75) ％,and there were significant differences in CD62p and PAC-1 among the groups(P ＜0.05).The genotypes of extensive metabolism was high in the response to clopidogrel,while those of intermediate metabolism were moderate and poor metabolism were low.Conclusion Intermediate metabolism genotype patients could be adjusted to the dose of clopidogrel or the use of other antiplatelet drugs,and the poor metabolism genotype patients should be used other antiplatelet drugs.
